Budget Impact Analysis of Tocilizumab Versus Adalimumab As A First Line (1l) Monotherapy For The Treatment of Patients With Rheumatoid Arthritis (Ra) In Greece
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2279
https://www.valueinhealthjournal.com/article/S1098-3015(15)04355-7/fulltext
Title :
Budget Impact Analysis of Tocilizumab Versus Adalimumab As A First Line (1l) Monotherapy For The Treatment of Patients With Rheumatoid Arthritis (Ra) In Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04355-7&doi=10.1016/j.jval.2015.09.2279
First page :
A639
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1687